Research

DehydraTECH™ Research

The safety and effectiveness of Lexaria’s DehydraTECH technology has been studied in a series of controlled and well designed in vitro and in vivo studies, examining factors such as total bioabsorption directly and indirectly through surrogate biomarkers, time to onset of effectiveness, flavor appeal and quality of effectiveness.

Research

shutterstock_1022751304

Lexaria's completed R&D research programs and milestones. Each study or milestone includes a brief synopsis of the study with a link to follow for more information.

Lexaria’s Submits Investigational New Drug Application – January 30, 2024

  • Planned U.S. phase 1b hypertension clinical trial HYPER-H23-1

Lexaria’s Patented Technology Improved the Oral Performance of the Rybelsus-Branded GLP-1 drug Semaglutide – January 04, 2024

Final results from a human pilot study show DehydraTECH-powered semaglutide outperforms Rybelsus:

  • Sustained higher levels of semaglutide in blood;
  • Better blood glucose control;
  • Faster achievement of peak drug delivery; and
  • Reduced side effects.

Lexaria’s Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study – November 28, 2023

DehydraTECH-powered semaglutide achieved these benefits in a human pilot study compared to Rybelsus®:

  • Sustained lower levels of blood glucose from baseline including nearly 10x lower after 24 hours;
  • Lower blood-glucose spike after eating; and
  • Successful first-ever DehydraTECH test with a “large molecule” drug.

Lexaria’s Technology Improves the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide in Human Pilot Study – November 27, 2023

DehydraTECHTM-powered semaglutide achieved these benefits in a human pilot study compared to Rybelsus®:

  • Sustained higher levels of semaglutide in blood;
  • Faster achievement of peak drug delivery; and
  • Reduced side effects.

Lexaria Granted Two New Patents in Canada – October 12, 2023

  • Lexaria now holds 37 granted patents world-wide.

Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD – September 21, 2023

  • DehydraTECH-powered GLP-1 drugs will be evaluated for potential improvements such as:
    • Reduced side effects;
    • Enhanced weight loss;
    • Improved health outcomes for diabetes and other conditions;
    • Improved oral bioavailability;
    • Reduced cost.

Lexaria’s DehydraTECH-Nicotine Faster than ZYN and on! – August 9, 2023

  • DehydraTECH-Nicotine reaches maximum blood saturation levels faster than world-leading brands from Swedish Match and Altria in human study NIC-H22-1.

Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Product – July 19, 2023

  • More countries are banning e-cigarettes as novel oral products gain traction.

Lexaria Receives New Patents – June 20, 2023

  • Lexaria now holds 34 granted patents world-wide.

Lexaria’s DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study – June 16, 2023

  • Blood glucose levels reduced by 19.9% with DehydraTECH-CBD.

Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers – May 23, 2023

  • DehydraTECH-CBD offers distinctive mechanistic benefits related to its growing therapeutic utility.

Lexaria’s Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery – May 18, 2023

  • 900% and 2,000% improvements in peak bloodstream delivery using DehydraTECH.

cGMP Manufacturing Complete for Lexaria’s Upcoming U.S. Phase 1b Hypertension Clinical Trial – May 11, 2023

  • DehydraTECH-CBD is currently unique in its evidenced superior power to reduce blood pressure over other oral CBD formulations.

Lexaria’s Human Clinical Nicotine Study Completes Dosing as Planned – May 8, 2023

  • Dosing of the targeted 36 subjects in its human clinical oral nicotine study NIC-H22-1 has been completed.

Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study – April 24, 2023

  • Lexaria is working with its regulatory and clinical advisors toward upcoming IND submission.

Lexaria is Receiving Four New Patents – April 20, 2023

  • Japan, Australia, Canada and the USA.

Lexaria’s DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels – March 2, 2023

  • Study DIAB-A22-1 has completed and produced at least three positive outcomes including weight loss in obese diabetic-conditioned animals, together with improved triglyceride and cholesterol levels.

Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4 – February 21, 2023

  • DehydraTECH-processed cannabidiol (“CBD”) capsule formulation demonstrates a potentially novel mechanism of action in reducing blood pressure.

Lexaria Receives First Granted Patent In Canada – December 29, 2022

  • First granted patent in Canada and 28th granted patent worldwide.

Lexaria’s DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels – December 21, 2022

  • Lexaria has demonstrated superior cannabidiol (“CBD”) blood absorption levels from its patented DehydraTECH-CBD™ relative to those of published, pharmaceutical-grade CBD industry comparators.

Lexaria’s DehydraTECH-CBD(TM) Enhances Performance Compared to Epidiolex(R) in Seizure Study Program – November 29, 2022

  • Lexaria’s patented DehydraTECH-CBD™ has demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex®.

Lexaria Examining Potential Therapeutic Use of DehydraTECH-CBD in Dementia – November 10, 2022

  • This is Lexaria’s first-ever study to investigate whether its patented DehydraTECH-processed cannabidiol (“CBD”) may potentially have therapeutic utility against dementia.

Lexaria Starts Study Evaluating the Effect of DehydraTECH-CBD on Diabetes – November 8, 2022

  • This is Lexaria’s first-ever study to investigate whether its patented DehydraTECH-processed cannabidiol (“CBD”) may potentially have therapeutic utility against diabetes.

Lexaria’s Human Clinical Hypertension Study a Success – October 27, 2022

HYPER-H21-4 using DehydraTECH-CBD evidenced:

  • Exceptional safety and tolerability
  • Statistically significant lowering of 24-hour ambulatory blood pressure (“BP”)
  • BP lowered for the entire 5-week study duration
  • BP lowered both for patients currently taking other antihypertensive drugs as well as patients not taking any other antihypertensive drugs

Lexaria Receives New Patent in Mexico – August 31, 2022

  • Newest granted patent expands worldwide patent portfolio to 27

Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension – August 10, 2022

  • Significant Milestone Achieved in Commercial Product Development Program

Lexaria’s DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events – July 27, 2022

  • HYPER-H21-4 is designed to enhance Lexaria’s probability of success toward an Investigational New Drug application filing with the FDA

Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing – July 14, 2022

  • 26th worldwide patent and the first patent issued from Lexaria’s seventh patent family

Lexaria’s Human Nicotine Study Nearing Start Date – July 13, 2022

  • Lexaria is targeting the oral nicotine pouch category, one of the fastest growing segments of the nicotine industry

Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs – April 21, 2022

  • 25th patent grant is Lexaria’s first-ever patent for the enhanced delivery of antivirals

Lexaria’s Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results – April 14, 2022

  • Data From This Human Study, Together With the Findings From Lexaria’s Other Previously Announced Successful Studies, Intended To Support the Company’s Plans To Seek Approvals by the U.S. Food and Drug Administration

Lexaria Begins New Nicotine Formulation Creation and Evaluation Program – April 11, 2022

  • Lexaria will receive a fee to provide certain DehydraTECH powder-based nicotine formulations to be evaluated by Altria. The new agreements are in effect until March 31, 2023

Lexaria Granted Important New Oral Nicotine Patent – March 08, 2022

  • Newest granted patent expands worldwide patent portfolio to 24

Lexaria Reports Potentially Ground Breaking Findings in Sildenafil Animal Study – February 2, 2022

  • DehydraTECH sildenafil delivered 74% more drug at 4 minutes, than the control

Lexaria’s DehydraTECH™-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2 – December 8, 2021

  • Testing confirms that DehydraTECH-processed cannabidiol reduces arterial stiffness, potentially broadening application to treatment of cardiovascular and other diseases beyond hypertension.

Lexaria Announces Ambitious New Hypertension Study – November 3, 2021

  • HYPER-H21-4 will be the most comprehensive study ever undertaken by Lexaria. It is expected to consist of 60 volunteers between the ages of 45-70 using three 150 mg doses of DehydraTECH-CBD, every day for the 6-week duration of the study

Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol – November 1, 2021

  • Study to compare effectiveness of FDA-approved Epidiolex to DehydraTECH-CBD for reducing seizure activity
  • Experts in respirology and neurobiology are among the talented team assembled to conduct the study, which is designed to investigate if DehydraTECH-CBD has similar or superior levels of efficacy in treating seizures as does the world’s only CBD-based seizure medication, Epidiolex

Lexaria’s Technology Proven to Deliver Oral THC More Effectively – October 13, 2021

  • DehydraTECH delivers equivalent quantity of oral THC three times faster: 15 minutes vs. 45 minutes

Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results – October 5, 2021

  • DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls
  • Peak levels achieved were up to 10x higher than controls

Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension – September 8, 2021

  • Positive results using DehydraTECH-CBD support progressing to FDA IND application oral

Lexaria’s Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period – September 7, 2021

  • Human Clinical Study HYPER-H21-2 evidences up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD relative to placebo

Lexaria’s DehydraTECH-CBD Lowers Blood Pressure – July 29, 2021

  • Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability

Lexaria’s DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3 – July 21, 2021

  • Demonstrated significant enhancement in antiviral drug delivery using DehydraTECH-enabled Colchicine
  • Possible benefits for treating SARS-CoV-2/COVID-19 and mRNA vaccine side effects

Lexaria Completes Successful Antiviral Drug Molecular Characterization Study with Canada’s National Research Council – July 15, 2021

  • Successfully confirmed Lexaria’s molecular characterization study objectives, demonstrating DehydraTECH processing and formulation technology does not create a covalently bonded new molecular entity (“NME”), and that each drug tested remained stable and did not undergo change in chemical structure
  • These findings are strongly supportive of accelerated regulatory filings such as the 505(b)(2) pathway permitted by the Food and Drug Administration (“FDA”) and other international regulators

Lexaria’s Newest DehydraTECH 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates its Strongest CBD Absorption Results Ever – May 20, 2021

  • New formulation delivers up to 2,708% more CBD into bloodstream

Lexaria Records Successful Results from First 2021 Study, HYPER-A21-1 – May 6, 2021

  • Up to 2,178% more CBD delivered into bloodstream
  • Up to 1,737% more CBD delivered into brain tissue

Lexaria’s Patented Technology Significantly Enhances Oral Delivery of Antiviral Drugs – December 1, 2020

  • Improved delivery of both Protease Inhibitor (Darunavir) and Reverse Transcriptase Inhibitor (Efavirenz) drugs exhibited improved bioavailability rate as high as 54%
  • Demonstrates improved delivery of Darunavir and Efavirenz, two classes of drugs in use against HIV/AIDS and under investigation against SARS-CoV-2/COVID-19

Lexaria’s DehydraTECH Formulation Delivers 475% More CBD to Bloodstream after 15 Minutes than Conventional Industry Formulations – May 15, 2019

  • DehydraTECH delivered measurable quantities of CBD into blood in as little as 2 minutes
  • DehydraTECH delivered 475% more CBD to bloodstream
  • The area under the curve (“AUC”) for Lexaria’s patented DehydraTECH was 389% more than the MCT oil control formulation

Cardiovascular Performance Improvements Including Lower Blood Pressure Discovered from Human Clinical Trial using Lexaria’s DehydraTECH Powered TurboCBD Capsules – February 21, 2019

  • A single 90mg dose of TurboCBD provided evidence of lower blood pressure; higher blood flow to the brain; faster delivery onset of CBD into the bloodstream; and larger quantities of CBD within the blood compared to a single 90mg dose of generic CBD

Lexaria Bioscience Announces Further Advancement of Edibles Nicotine Testing Delivery Measured Within Minutes – August 7, 2018

  • 90% more nicotine delivered at 10-minute mark
  • 70% more nicotine delivered overall within first 15 mins of study
  • 94% more nicotine delivered over the 60 min study period
  • 295% higher brain levels of nicotine where nicotine effects are focused, compared to controls

Significant Bioavailability Results in Human Clinical Trial using Lexaria’s DehydraTECH Powered TurboCBD™ Capsules – August 1, 2018

  • Lexaria’s TurboCBD capsules delivered 317% more CBD to bloodstream

Lexaria Achieves Significant Breakthrough in Alternative Nicotine Delivery Technology – April 17, 2018

  • 148% improvement in peak nicotine delivery to the bloodstream relative to controls
  • 1,160% faster delivery of nicotine to the bloodstream than achieved with controls
  • 560% higher brain levels of nicotine where nicotine effects are focused, compared to controls

Lexaria Bioscience Corp. Completes Successful Skin Absorption Study – March 13, 2018

  • As much as a 225% increase in CBD permeability when compared to the highest performing commercial penetration enhancer formulation assessed
  • Almost a 1,900% increase in CBD permeability when compared to a control formulation that was devoid of both the DehydraTECH technology or any commercial penetration enhancers

Lexaria’s groundbreaking research into DehydraTECH-CBD in published papers

Journal of Functional Foods – November 2023

  • Antihypertensive effects of CBD are mediated by altered inflammatory response: A sub-study of the HYPER-H21-4 trial.

Advances in Therapy – June 2023

  • The Influence of Oral Cannabidiol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Untreated Hypertension: A Double-Blind, Placebo-Controlled, Cross-Over Pilot Study.

Pharmaceuticals – April 2023

  • Trial of a Novel Oral Cannabinoid Formulation in Patients with
    Hypertension: A Double-Blind, Placebo-Controlled Pharmacogenetic Study.

International Journal of Molecular Sciences – June 2023

  • Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study.

Biomedicine & Pharmacotherapy – June 2023

  • Effects of CBD supplementation on ambulatory blood pressure and serum urotensin-II concentrations in Caucasian patients with essential hypertension: A sub-analysis of the HYPER-H21-4 trial.

Cannabis and Cannabinoid Research – April 2023

  • Chronic Effects of Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure in Patients with Hypertension (HYPER-H21-4): A Randomized, Placebo-Controlled, and Crossover Study.

Biomedicine & Pharmacotherapy – April 2023

  • CBD supplementation reduces arterial blood pressure via modulation of the sympatho-chromaffin system: A substudy from the HYPER-H21-4 trial.

Journal of Personalized Medicine – June 2022

  • Chronic Effects of Effective Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure and Vascular Outcomes in Treated and Untreated Hypertension (HYPER-H21-4): Study Protocol for a Randomized, Placebo-Controlled, and Crossover Study.

Advances in Therapy – September 2019

  • Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study.

Sign up to receive our news and updates